

Munich Re Group

Quarterly statement as at 31 March 2024

8 May 2024

Christoph Jurecka (CFO)



Quarterly Statement as at 31 March 2024

Agenda

















O1 Munich Re

Good start to the year with earnings above pro-rata guidance



Better-than-expected operating performance in all lines, favourable capital markets







RI net result Q1 2024 (Q1 2023):

€1,888m (€1,051m)

High investment return (Rol 4.5%¹) and strong technical results in both segments; below-average major losses in p-c

Property-casualty: Combined ratio: 75.3% (86.5%) – major-loss ratio: 9.9% (16.4%), reserve releases²: -5.0% (-5.0%) net result: €1,336m (€760m)

Life and health: Total technical result: €586m (€320m) net result: €552m (€291m)

April renewals: Risk-adjusted price change: ~ -0.7%. premium change: +6.1%

ERGO net result Q1 2024 (Q1 2023):

€252m (€219m)

Strong results in P-C Germany and International; L&H Germany with solid performance despite elevated claims

Life and Health Germany: Total technical result: €225m (€258m) net result: €36m (€41m)

Property-casualty Germany: Combined ratio: 84.4% (81.2%) – net result: €150m (€166m)

International: Combined ratio: 89.5% (95.4%) -

net result: €65m (€12m)

Capital position





Change in unrealised gains/losses

Investments —€852m
Insurance contracts €58m

Return on equity

 Reinsurance
 28.9%

 ERGO
 19.5%

Solvency II ratio

273%

Investments



Q1 2024

Investment portfolio¹



3-month reinvestment yield



Portfolio management

- Slight reduction of equity quota to 4.0% (2.8% net of hedges)
- Investments in corporate bonds and emerging market bonds safeguard a strong reinvestment yield of 4.6%

¹ Management view – not fully comparable with IFRS figures, e.g., including real-estate in own use and cash. Fair values as at 31.3.2024 (31.12.2023). 2 Developed markets. 3 Including derivatives: 2.8% (3.7%).

Investment result



	Q1			Q1		
€m	2024		Return ¹	2023		Return ¹
Regular income	1,807		3.2%	1,601		3.0%
Write-ups/write-downs	-48	I	-0.1%	-28	1	-0.1%
Change in expected credit loss (ECL)	25	1	0.0%	-38	I	-0.1%
Disposal gains/losses	-55	I	-0.1%	166	-	0.3%
Fair-value change	586		1.0%	74	1	0.1%
Other income/expenses	-152		-0.3%	-164		-0.3%
Investment result	2,163		3.8%	1,612		3.0%

	Fixed income	Equities	Other	Fixed income	Equities	Other
Write-ups/write-downs	0	0	-48	0	0	-28
Disposal gains/losses	–76	0	20	-189	0	355
Fair-value change	-93	576	103	-46	252	-131



02

ERGO

ERGO Life and Health Germany




Key messages

- Total technical result of life and long-term health business in line with expectation
- Elevated claims expenses in short-term health and travel business
- Net result of €36m




Insurance revenue (gross)

€m




Increase of insurance revenues in short- and long-term health insurance, life new book and travel; decrease in life back book

Total technical result



- CSM release in life and longterm health at €211m
- Short-term business (PAA) contribution of €23m to total technical result

Contractual service margin (CSM)¹



 Increase driven mainly by capital market related effects exceeding CSM release

1 Net of reinsurance. Quarterly Statement as at 31 March 2024 8 May 2024 9

ERGO Property-casualty Germany



Key messages

 Total technical result at strong level supported by low large losses and good operating performance




 Very high net result of €150m also driven by excellent investment result

Insurance revenue (gross)

€m


Increase mainly driven by fire/property and other (esp. engineering)

Total technical result



Combined ratio

%



- Total technical result/combined ratio in Q1 2024 driven by
 - Significantly lower-thanexpected major losses
 - Good operating performance
 - Combined ratio includes discount benefit of ~3pp
 - Seasonality of costs
- Q1 2023 with exceptionally low basic and large losses

8 May 2024 10

ERGO International



Key messages

 Strong total technical result in p-c driven by excellent claims development and profitable growth



- Good technical development in life/health
- Net result of €65m


Insurance revenue (gross)

€m



Increase mainly from Poland P-C, Spain Health and Thailand P-C


Total technical result



- Excellent combined ratio of 89.5% (95.4%) driven by:
 - Benign large loss development
 - Strong operating performance
- Life/health: CSM release in line with expectation, e.g., in Spain Health and Belgium Life and Health

Contractual service margin (CSM)¹

€m



- Increase mainly driven by:
 - Operating changes, mostly from Belgium Health
 - Contribution from new contracts in the Spanish and Belgian health business



03

Reinsurance

Life and health reinsurance



Key messages

- Very strong total technical result, exceeding pro-rata guidance
- Favourable biometric experience and positive FX impact
- Pleasing new business development, especially in North America




Insurance revenue (gross)

€m




Growth driven by North America and UK

Total technical result



- Insurance service result supported by strong new business and positive experience variances
- High result contribution from FinMoRe business

Contractual service margin (CSM)¹



 High contribution from new business, including large transactions in North America

1 Net of reinsurance. Quarterly Statement as at 31 March 2024 8 May 2024 13

Property-casualty reinsurance



Key messages


- Revenue growth of 5.1% vs. Q1 2023
- Very pleasing combined ratio of 75.3% supported by benign major losses



 Normalised combined ratio of 79.5% better than FY guidance


Insurance revenue (gross)

€m




- XL business: increased prices in nat cat
- Global Specialty Insurance: ongoing growth across all units

Total technical result



Combined ratio



- Below-average major losses of 9.9% driven by benign nat cats, while Q1 2023 was impacted by earthquake in Turkey
- Collapse Francis Scott Key Bridge single biggest loss event in Q1
- Normalised combined ratio better than expected driven by favourable development of basic losses
- Combined ratio includes discount benefit of ~7.5%

April renewals – Continued trend of profitable growth, high portfolio quality maintained





Selective growth and portfolio optimisation

- Another good renewal in an ongoing attractive market environment – strong pricing improvements of past years preserved
- Quality of the portfolio maintained by defending achieved improvements of terms and conditions (including higher attachment points) or implementing further risk-mitigating measures
- Expansion of casualty proportional business which benefited from sizeable original rate increases, e.g., European motor
- Nat cat exposure in Japan slightly decreased
- Excluding portfolio mix effects, price change continued to increase by +0.6%

April only


7.6%

11.1%

17.1%

25.7%

¹ Price change is fully risk-adjusted, considering most recent inflation and loss-trend assumptions. Calculation until 2023 based on gross written premium (IFRS 4). From 2024 calculation of price change based on insurance revenue (IFRS 17), i.e. premiums are adjusted for ceding commissions which leads to shifts in portfolio weights (stronger weighting of non-proportional business) and a smaller denominator. 2 Volume change still based on GWP.



04

Outlook

Outlook 2024



Group	Insurance revenue (gross)	Net result	Return on investment	
	~€59 bn	~ €5.0 bn	> 2.8 %	
ERGO	Insurance revenue (gross)	Net result	Combined ratio P-C Germany	Combined ratio International
	~ €20 bn	~ €0.8 bn	~87%	~90%
Reinsurance	~€20bn Insurance revenue (gross)	~€0.8bn Net result	~87% Combined ratio Property-casualty	~90% Total technical result Life and health

Disclaimer



This presentation was prepared exclusively for investors in financial instruments issued by Munich Re and contains forward-looking statements that are based on current assumptions and forecasts of the management of Munich Re. Known and unknown risks, uncertainties and other factors could lead to material differences between the forward-looking statements given here and the actual development, in particular of the results, financial situation and performance of our Group. Obvious fluctuations in the incidence of major losses in addition to the pronounced volatility of the capital markets and exchange rates — as well as the special features of IFRS accounting — make an accurate forecast of results impossible. The Group assumes no liability to update these forward-looking statements or to make them conform to future events or developments. Due to rounding, there may be minor deviations in summations and in the calculation of percentages in this presentation.